Testosterone cypionate cycle does not increase the incidence of adverse reactions to cytotoxic chemotherapy. Adverse events observed with equal frequency in patients treated with chemotherapy and placebo / chemotherapy.
Body as a whole: often – fatigue, generalized weakness, inflammation of mucous membranes (mucositis), anorexia; infrequently – nonspecific pain; rarely – worsening of rheumatoid arthritis.
Musculoskeletal System: often – pain in the chest, bone pain (especially in the bones active hematopoiesis) and muscles (weak or moderate (10%), sometimes severe (3%), which in most cases cropped conventional analgesics).
Gastrointestinal tract: often – nausea, vomiting; often – constipation, diarrhea.
Cardiovascular system: in rare cases – transient hypotension, not requiring medical correction, vascular disorders (venookklyuzionnaya disease, disorders associated with a change in the fluid content in the body, in patients treated with high-dose chemotherapy followed by autologous bone marrow transplantation; communication with receiving has not been established).
Respiratory system: often – cough, sore throat; rarely – pulmonary infiltrates, interstitial pneumonia, pulmonary edema, and in rare cases with unfavorable outcome of respiratory failure or adult respiratory distress syndrome (can be fatal).
Skin and subcutaneous fat: often – alopecia, skin rash; rarely – Sweet’s syndrome (febrile acute dermatosis, a significant proportion of these patients suffered from leukemia, which is often accompanied by the development of Sweet’s syndrome, so that the connection with the reception of testosterone cypionate cycle has not been established), cutaneous vasculitis (development mechanism in patients receiving , is not known ).
Nervous system: often – headache.
Immune system: rare – allergic reactions. About half of allergic reactions associated with the administration of the first dose, more often – after / in the drug. Sometimes resumption of treatment is accompanied by a relapse of symptoms.
Genito-urinary system: rarely – a violation of urination (dysuria generally mild to moderate).
Laboratory findings: very often – increasing the activity of lactate dehydrogenase, alkaline phosphatase, g-glutamyl transferase, an increase in serum uric acid concentration (reversible dose-related changes are usually mild or moderate).
Patients with HIV infection
Musculoskeletal system: very often – pain in bones and muscles (myalgia), mainly mild or moderate (frequency similar to that of patients with oncological diseases).
Blood and lymphatic system: often – splenomegaly (linked to drug intake at least 3% of cases; in all cases, physical examination, there was a slight or moderate degree of splenomegaly with a favorable clinical course, been no cases of hypersplenism, splenectomy was not carried out in any case). Splenomegaly often occurs in patients suffering from HIV infection, as well as varying degrees of symptoms occurs in most patients with AIDS; in such cases the connection with the reception has not been established.
Healthy donors (allogeneic PBSC mobilization)
Body as a whole: . Rarely – worsening of rheumatoid arthritis Musculoskeletal System: often – pain in the bones and muscles, mainly mild or moderate. Respiratory system: rare – hemoptysis, pulmonary infiltrates. The nervous system: very often – headache . immune system: . rare – severe allergic reaction Blood and lymphatic system: very often – leukocytosis (more than 50 x 10 9 / l) was observed in 41% of healthy donors, transient thrombocytopenia (less than 100 x 10 9 / l) was observed in 35% healthy donors; often – splenomegaly (without clinical signs); seldom – disorders of the spleen function. Laboratory tests: often – a transient slight increase in lactate dehydrogenase, alkaline phosphatase; infrequently – a slight increase in the activity of aspartate aminotransferase (AST) (no clinical sequelae), testosterone cypionate cycle hyperuricemia.
Patients with TXH
The frequency of adverse events while taking the drug Neupogen ® patients with TXH decreases over time.
Body as a whole: often – reactions (including pain) at the injection site (less than 2% of patients), arthralgia (less than 2% of patients). Musculoskeletal System: often – pain in bones and muscles; . often – osteoporosis (less than 2% of patients) Gastrointestinal tract: often – diarrhea (usually after the start of therapy), hepatomegaly (less than 2% of patients). Skin and subcutaneous fat: often – alopecia (less than . 2% of patients), rash (less than 2% of patients) cutaneous vasculitis (2% of patients) Nervous system: often – headache (less than 2% of patients, usually after the beginning of therapy). Blood and lymphatic system : often – anemia, splenomegaly (in some cases can progress); often – thrombocytopenia; seldom – disorders of the spleen function. Also identified cases of epistaxis. Genito-urinary system:rarely – hematuria, proteinuria. Laboratory findings: very often – transient increase in lactate dehydrogenase, alkaline phosphatase, without clinical manifestations, moderate transient hypoglycemia after eating, hyperuricemia.
Postmarketing use of the drug
Immune system: In rare cases, the allergic reactions, including anaphylaxis, skin rash, hives, testosterone cypionate cycle which can develop at the start of therapy or during subsequent treatment filgrastim. In some cases, accompanied by a resumption of treatment a relapse of symptoms, suggesting a relationship between the drug and the adverse event. steroiden kaufen
anabolika steroide kaufen
anabolika steroide kaufen